ABOUT US | CONTACT | IAPAC HOME 
 

ATLIS 2010 HOME

ABOUT ATLIS 2008

ATLIS 2008 PRESS RELEASE

ATLIS 2008 KEY FINDINGS

ATLIS FINDINGS

GENERAL HEALTH STATUS

CURRENT AND FUTURE MEDICATIONS

PRIORITIES FOR FUTURE MEDICATIONS

CONCERNS ABOUT HIV STATUS

CURRENT SEX PRACTICES

News Release

______________________________________________________________________

 

Media Contacts: Bora Lee
Cohn & Wolfe
(212) 798-9522
bora.lee@cohnwolfe.com
  Thomas Eck
Cohn & Wolfe
(212) 798-9733
thomas.eck@cohnwolfe.com



Landmark Global Survey Shows HIV-Positive Patients Still Fear Stigma

More than 25 Years After the Start of the Pandemic

 

Side Effects Remain Major Barrier to Treatment

 

IAPAC Issues Urgent Global Call-To-Action to Increase HIV Literacy

 

MEXICO CITY, 4 AUGUST 2008 – Results from the groundbreaking AIDS Treatment for Life International Survey (ATLIS), which polled nearly 3,000 HIV-positive patients from 18 countries, show an urgent global need for improved HIV and AIDS understanding and increased dialogue about quality of life.  Although great strides have been made in HIV education, the survey indicates people living with HIV and AIDS around the globe still live in fear of the societal stigma that surrounds the disease, and some are so concerned about side effects that they have chosen to stop their treatment regimens.  These and other ATLIS findings were released today by the International Association of Physicians in AIDS Care (IAPAC) at AIDS 2008 (the 17th International AIDS Conference) in Mexico City, Mexico, and were simultaneously published in the July/August 2008 issue of the Journal of the International Association of Physicians in AIDS Care (JIAPAC). 

 

            In light of the ATLIS findings, IAPAC encourages a global call-to-action urging the HIV community to: 1) increase education and discussion to ensure patients are better informed about their treatments and can assist in making decisions about their HIV therapy regimen; 2) promote dialogue around patients' quality of life as it relates to treatment potency, dosing strategies, side effects and tolerability; 3) address non-clinical barriers to HIV treatment initiation and adherence, including stigma, discrimination and cost; and 4) advance culturally sensitive HIV prevention programs.

 

People Still Hiding HIV Status Because Of Discrimination and Stigma

            The ATLIS findings suggest that stigma remains an issue for HIV-positive patients, particularly with regard to disclosure of their HIV status.  More than half of survey respondents (54 percent) are “very” or “somewhat” concerned about others knowing their HIV status, with 83 percent claiming this is predominantly due to concern of social discrimination and stigma.  They are also concerned about specific repercussions including the loss of family and friends (41 percent), the impact on their ability to establish future relationships (37 percent), the risk of losing their job (36 percent) and the impact on their reputation (36 percent).  African respondents had fewer concerns about revealing their condition as opposed to respondents in other regions.  Asian/Pacific respondents were more concerned about the risk of losing family and friends, as well as the potential impact on their current relationships. Respondents in North America were most concerned that their HIV-positive status could be damaging to their reputation.

 

Treatment Advances Applauded But Side Effects Remain a Significant Challenge

            Study results show that concerns about side effects may prevent patients from seeking treatment.  Overall, 26 percent of the respondents reported that they had elected not to seek treatment, because they believe that antiretroviral therapy (ART) causes too many side effects, with responses from Europe (42 percent) and South Africa (29 percent) being most prevalent. 

 

            “When the HIV and AIDS pandemic began in the early 1980s, the overarching goal of education was to give people hope and the goal of treatment was to prolong life,” said José M. Zuniga, Ph.D., President/CEO of IAPAC.  “Despite the incredible strides we have made, what this study shows is that some people are rejecting life-saving treatments, because they fear the side effects of the medications that could potentially save their lives, while others on treatment have unnecessarily resigned themselves to live with side effects and poor tolerability in an age where less toxic treatment options are available.  Patients can and should now expect more from their HIV treatment.”

 

            While the ATLIS results show that people living with HIV and AIDS believe the potency and overall efficacy of ART has been proven to help patients live longer lives, their concern centers around a number of short- and long-term side effects.  Thirty-four percent of treatment-experienced respondents discontinued their treatment primarily because they believed it caused too many side effects.  ATLIS found that more than half of all respondents worried that their medications will cause one or more of the following: face or body shape changes (58 percent), gastrointestinal problems (54 percent), fatigue or anemia (54 percent) and liver disease (54 percent).  Respondents in Latin America and North America voiced significantly more concern about many potential side effects than respondents from other regions (P < 0.05), while African respondents voiced significantly less concern (P < 0.05).  Female respondents in most regions, especially those in Europe, worried more than male respondents in their respective regions about bone loss and face or body shape changes. 

 

Improvement in Global HIV Literacy Needed

            Based on the ATLIS findings, there is a strong need for continued education on a global level about critical HIV and AIDS topics.  Overall, 69 percent of respondents said they wished they knew more about HIV and its treatment. This was most commonly voiced by respondents from Latin American (78 percent) and Africa (71 percent).

 

            When respondents were asked to describe how HIV drug resistance develops, only 17 percent accurately answered the question.  Fifty-four percent answered incorrectly or did not know the answer and 29 percent provided only partially accurate answers.  North American (48 percent) and Asian/Pacific (20 percent) respondents were most likely to select the correct answer to the question, whereas African respondents were more likely to select an inaccurate answer or did not know (79 percent), followed by respondents from Latin America (58 percent) and Europe (54 percent).  Previous studies have shown a strong correlation between a good understanding of HIV drug resistance and improved treatment adherence.

 

            “ATLIS results indicate there is still a strong need to educate HIV-positive patients and the world around them. The findings demand an increase in global HIV and AIDS literacy,” said Dr. Zuniga. “It is critical that we empower HIV-positive patients to take an active part in the management of their disease by educating them on the importance of adhering to their treatment and teaching them about the innovations in treatment that could improve their overall quality of life.”

 

 

The Face of HIV Has Dramatically Changed

            The ATLIS findings show that nearly half of those patients surveyed (48 percent) reported being in a heterosexual relationship, reinforcing that HIV is reaching broader populations.  A third of total respondents claimed to be in monogamous relationships.  African respondents were the most likely to be in a monogamous relationship.  Conversely, respondents in North America (25 percent) and Europe (21 percent) were most likely to have sex with casual partners.  Respondents in Latin America were more likely not to disclose their current sex practices.

 

About ATLIS

            ATLIS is the largest, multi-country, comparative, treatment awareness survey of people living with HIV and AIDS.  Its main objectives were to:

  • Evaluate and understand treatment awareness and practices worldwide
  • Assess the different social and cultural factors that impact people living with HIV and AIDS
  • Identify how currently available treatments affect the lives of HIV-positive people

 

            IAPAC worked with Ipsos Insight Health, an independent marketing research firm, to survey HIV-positive adults from five regions in a convenience sample: North America (United States), Latin America (Argentina, Brazil, Mexico and the Caribbean*), Europe (France, Germany, Italy, Russia, Spain and the United Kingdom), Asia/Pacific (Japan, Korea, Malaysia, New Zealand and Singapore), and Africa (South Africa). 

            ATLIS was conducted from March through May 2008 via a combination of Internet, phone and in-person recruitment methods by Ipsos Insight Health.  Interviews were conducted with a total of 2,968 HIV-positive adults (2,049 male and 919 female).  To mirror the actual population with HIV, specific effort was made to recruit both treatment-experienced and treatment-naïve respondents.  All respondents signed confidentiality/non-disclosure agreements prior to initiating the survey to ensure any information they shared would be kept confidential in accordance with local laws.  The questionnaire itself was translated in local languages, and was slightly tailored for each country to include socially acceptable language.

The methodology used in the ATLIS study is quantitative.  Results were based upon a convenience sample of HIV-positive people within each of the countries of interest.  Results are summarized using percentages.  Confidence intervals are not given, however, 95 percent confidence intervals for individual proportions based on the global sample (n = 2,968) will have margins of error within ±0.02.  Confidence intervals for a proportion from a specific segment will have larger margins of error (about ± 0.07 for n = 200 and ± 0.10 for n = 100).

 

            ATLIS was made possible through an educational grant provided by Merck & Co., Inc., Whitehouse Station, NJ USA, which operates in many countries as Merck Sharp & Dohme.

 

About IAPAC

            With offices in Chicago, Johannesburg, Washington, DC and Toronto, IAPAC represents more than 12,000 physicians and other healthcare professionals in over 100 countries.  IAPAC's mission is to craft and implement global educational and advocacy strategies, as well as technical assistance programmes to improve the quality of care provided to all people living with HIV and AIDS. 

 

For further information on IAPAC and ATLIS, please visit: www.iapac.org.

 

###

*Caribbean includes responses from the Dominican Republic, Jamaica and Puerto Rico.

 

 
line
©2011 International Association of Physicians in AIDS Care. All Rights Reserved.